|
|
References
1. Hofmann A. LSD: My Problem Child. published by
MAPS (The Multidisciplinary Association for Psychedelic Studies), 2005, pp.
45-6.
2. Branconnier, R. “The Efficacy of the Cerebral Metabolic Enhancers in the
Treatment of Senile Dementia.” Psychopharmacology Bulletin, 1983, vol. 19, no.
2, pp. 212-20.
3. Hofmann A., personal communication, January, 2006.
4. Speigel R. “A Controlled Long-Term Study with Hydergine, in Healthy Elderly
Volunteers.” Journal of the American Geriatrics Society, 1983, 31, no. 9, pp.
549- 555.
5. Copeland, R.L., Jr., Bhattacharyya, A.K., Aulakh, C.S., Pradham, S.N.
1. “Behavioral and Neurochemical Effects of Hydergine in Rats.” Archives of
International Pharmacodynamics, 1981, vol. 252, pp. 113-23.
6. Hindmarch, I., Parrott, A.C., Lanza, M. “The Effects of an Ergot Alkaloid
Derivative (Hydergine) on Aspects of Psychomotor Performance, Arousal, and
Cognitive Processing Ability.” The Journal of Clinical Pharmacology,
November-December 1979, pp. 726-31.
7. Emmenegger, H., Meier-Ruge, W. “The Actions of Hydergine on the Brain.”
Pharmacology, 1968, vol. 1, pp. 65-78.
8. Emmenegger, H., Meier-Ruge, W., ibid.
9. Emmenegger, H., Meier-Ruge, W., ibid.
10. Bertoni-Freddari C., Fattoretti P., Casoli T., Spanga C., Meier-Ruge W.
“Morphological Alterations of Synaptic Mitochondria During Aging.”
2. The Effect of Hydergine Treatment in the Pharmacology of the Aging
Process--Methods of Assessment and Potential Interventions. Editors:
3. Imre Zs-Nagy and Kenichi Kitani, New York Academy of Sciences, 1994.
11. Copeland, R.L., Jr., Bhattacharyya, A.K., Aulakh, C.S., Pradham, S.N.
“Behavioral and Neurochemical Effects of Hydergine in Rats.”
4. Archives of International Pharmacodynamics, 1981, vol. 252, pp. 113-23.
12. Copeland, R.L., Jr., Bhattacharyya, A.K., Aulakh, C.S., Pradham, S.N., ibid.
13. Copeland, R.L., Jr., Bhattacharyya, A.K., Aulakh, C.S., Pradham, S.N., ibid.
14. Emmenegger, H., Meier-Ruge, W., ibid.
15. Copeland, R.L., Jr., Bhattacharyya, A.K., Aulakh, C.S., Pradham, S.N., ibid.
16. Rao B., Norris J. “A Double-Blind Investigation of Hydergine in the
Treatment of Cerebrovascular Insufficiency in the Elderly." John Hopkins Medical
Journal, 1971, vol. 130, no. 9 pp. 317- 323.
17. Rao B., Norris J., ibid.
18. Thompson, T.L. II, Filley, C.M., Mitchell, W.D. , et al. “Lack of Efficacy
of Hydergine in Petients with Alzheimer’s Disease.” New England Journal of
Medicine, 1990, vol. 323, pp 445-8.
19. Yesavage, J. A., Hollister, L.E., Burian, E. “Dihydroergotoxine:
5. 6-Mg versus 3-Mg Dosage in the Treatment of Senile Dementia. Preliminary
Report.” Journal of the American Geriatrics Society. 1979, vol. 27, no.
6. 2, pp.80-82.
20. Weil, C., ed. “Pharmacology and Clinical Pharmacology of Hydergine.”
7. Handbook of Experimental Pharmacology. Springer-Verlag, New York, 1978.
21. Debono. “Bromocryptine and Dopamine Receptor Stimulation.” British Clinical
Pharmacolology, 1976, vol. 3, pp. 977- 982.
22. International Antiaging Systems, Bromocriptine product information,
www.antiaging-systems.com/a2z/bromocriptine.htm
23. Lissoni P, Mandala M, et al. “Efficacy of bromocriptine in the treatment of
metastatic breast cancer- and prostate cancer-related hyperprolactinemia.” Neuro
Endocrinol Lett. 2000, vol. 21, no. 5, pp.
8. 405-408.
24. Luo S., Luo J, Cincotta A.H. “Association of the antidiabetic effects of
bromocriptine with a shift in the daily rhythm of monoamine metabolism within
the suprachiasmatic nuclei of the Syrian hamster.”
9. Chronobiol Int., March 2000, vol. 17, no. 2, pp.155-72.
25. Bray, G.A., Greenway, F.L. “Current and Potential Drugs for Treatment of
Obesity” Endocrine Reviews, 1999, vol. 20, no. 6, pp. 805-875.
26. Iliff L., DuBoulay G.H., Marshall J., et al. “Effect of nicergoline on
cerebral blood flow.” Journal Neurol. Neurosurg. Psychiatry, 1977, vol. 40, pp.
746-7.
27. Iliff L., DuBoulay G.H., Marshall J., et al., ibid.
28. Forette F., Varin D., Henry J.F., Hervy M.P., “Treatment of arterial
hypertension in the elderly with an alpha-blocker: nicergoline.” Nouv Presse
Med., Dec. 1980, vol. 20, no. 9(48), pp. 3685-8.
29. Caraci F., Chisari M., Frasca G., Canonico P.L., Battaglia A., Calafiore M.,
Battaglia G., Bosco P., Nicoletti F., Copani A., Sortino M.A. “Nicergoline, a
drug used for age-dependent cognitive impairment, protects cultured neurons
against beta-amyloid toxicity.” Brain Res.
10. 2005 Jun 14; vol. 1047, no. 1, pp. 30-7.
30. Vairetti M., Ferrigno A., Canonico P.L., Battaglia A., Berte F., Richelmi P.
“Nicergoline reverts haloperidol-induced loss of detoxifying-enzyme activity.”
Eur J Pharmacol, 2004, Nov 28, vol. 505, no. 1-3, pp. 121-5.
31. Takeshi N., Nobuhiko S., Shoei F., Ichiro A., Yukitsuka K., “Repeated
injections of nicergoline increase the nerve growth factor level in the aged rat
brain.” Japanese Journal Pharmacology, 1998, vol.
11. 76, no. 3, pp. 321-323.
32. Asai S., Zhao H., Yamashita A., Jike T., Kunimatsu T., Nagata T., Kohno T.,
Ishikawa K., “Nicergoline Enhances Glutamate Re-Uptake and Protects Against
Brain Damage in Rat Global Brain Ischaemia.” European Journal Pharmacology,
1999, vol. 383, no. 3, pp. 267-74.
33. BBC News, “Sex drug could aid male stamina.”
http://news.bbc.co.uk/1/hi/health/1949087.stm, April 24, 2002.
HOME
|